United States

People: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

20 Oct 2017
Change (% chg)

$-0.01 (-0.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Deshpande, Milind 

Dr. Milind S. Deshpande, Ph.D., is President, Chief Executive Officer, Director of the Company. Prior to that, he was our President of Research and Development and Chief Scientific Officer. Prior to joining Achillion in September 2001, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb, a pharmaceutical company, from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande is on the board of directors of Spero Therapeutics, a biotechnology company. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.

Basic Compensation

Total Annual Compensation, USD 868,960
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 4,078,780
Fiscal Year Total, USD 4,947,740

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Scheer


Milind Deshpande


Mary Fenton


Martha Manning


David Apelian


Joseph Truitt

As Of  30 Dec 2014